Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLY019
MIFTS: 57

Polyneuropathy

Categories: Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Polyneuropathy

About this section

MalaCards integrated aliases for Polyneuropathy:

Name: Polyneuropathy 12 29 55 6 15 73
Polyneuropathies 44

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 33


Sources

Summaries for Polyneuropathy

About this section
Disease Ontology : 12 A peripheral system disease that is characterized by is damage affecting peripheral nerves (peripheral neuropathy) in roughly the same areas on both sides of the body, featuring weakness, numbness, pins-and-needles, and burning pain.

MalaCards based summary : Polyneuropathy, also known as polyneuropathies, is related to amyloidosis, hereditary, transthyretin-related and demyelinating polyneuropathy, and has symptoms including neuralgia An important gene associated with Polyneuropathy is GDAP1 (Ganglioside Induced Differentiation Associated Protein 1), and among its related pathways/superpathways are Guidance Cues and Growth Cone Motility and Neural Crest Differentiation. The drugs Imipramine and Pregabalin have been mentioned in the context of this disorder. Affiliated tissues include liver, skin and testes, and related phenotypes are homeostasis/metabolism and cellular

Wikipedia : 76 Polyneuropathy (poly- + neuro- + -pathy) is damage or disease affecting peripheral nerves (peripheral... more...

Sources

Related Diseases for Polyneuropathy

About this section

Diseases in the Polyneuropathy family:

Polyneuropathy Due to Drug Chronic Polyneuropathy

Diseases related to Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 586)
# Related Disease Score Top Affiliating Genes
1 amyloidosis, hereditary, transthyretin-related 34.0 APOA1 GSN TTR
2 demyelinating polyneuropathy 33.9 MAG PMP22 TTR
3 chronic polyneuropathy 33.6 CD40LG MAG
4 amyloidosis, finnish type 33.4 GSN TTR
5 hereditary neuropathy with liability to pressure palsy 32.9 MPZ PMP22
6 neuropathy, hereditary, with liability to pressure palsies 32.7 GDAP1 MPZ PMP22
7 hypertrophic neuropathy of dejerine-sottas 32.5 GDAP1 MPZ PMP22
8 charcot-marie-tooth disease, demyelinating, type 1b 32.3 MPZ PMP22
9 diabetic neuropathy 32.3 AKR1B1 MPZ PMP22
10 guillain-barre syndrome 32.0 CD40LG MBP MPZ PMP22
11 miller fisher syndrome 31.3 CD40LG MAG
12 hereditary amyloidosis 30.9 APOA1 GSN TTR
13 charcot-marie-tooth disease, demyelinating, type 1f 30.8 MPZ PMP22
14 charcot-marie-tooth disease, demyelinating, type 1c 30.8 MPZ PMP22
15 amyloidosis 30.8 APOA1 GSN TTR
16 neuropathy 30.7 GDAP1 MPZ MT-ATP6 PMP22 PNPLA6
17 roussy-levy hereditary areflexic dystasia 30.6 MPZ PMP22
18 neuropathy, congenital hypomyelinating or amyelinating, autosomal recessive 30.6 GDAP1 MPZ PMP22
19 foot drop 30.6 MPZ PMP22
20 amyloid neuropathy 30.3 APOA1 GSN TTR
21 charcot-marie-tooth disease, x-linked dominant, 1 30.2 GDAP1 MPZ
22 mononeuritis multiplex 30.1 CD40LG MAG
23 charcot-marie-tooth disease, demyelinating, type 1a 30.0 GDAP1 MPZ PMP22
24 charcot-marie-tooth disease and deafness 30.0 GDAP1 MPZ PMP22
25 charcot-marie-tooth disease, axonal, type 2b 29.6 MPZ PMP22
26 charcot-marie-tooth disease, axonal, type 2e 29.6 GDAP1 MPZ PMP22
27 optic neuritis 29.5 MAG MBP MPZ
28 cryoglobulinemia, familial mixed 29.4 CD40LG IFNA2
29 hereditary neuropathies 29.4 MAG MBP MPZ PMP22
30 sensory peripheral neuropathy 29.3 GDAP1 MAG MPZ PMP22
31 polyradiculoneuropathy 29.2 MAG MBP MPZ PMP22
32 neuritis 29.1 MAG MBP MPZ PMP22
33 charcot-marie-tooth disease 29.1 GDAP1 MAG MBP MPZ MT-ATP6 PMP22
34 demyelinating disease 28.8 CD40LG MAG MBP
35 peripheral nervous system disease 28.1 CD40LG GDAP1 MAG MPZ PMP22 PNPLA6
36 chronic inflammatory demyelinating polyneuropathy 12.4
37 polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract 12.3
38 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 12.3
39 diabetic polyneuropathy 12.2
40 critical illness polyneuropathy 12.2
41 polyendocrine-polyneuropathy syndrome 12.2
42 ataxia and polyneuropathy, adult-onset 12.1
43 subacute inflammatory demyelinating polyneuropathy 12.0
44 paraneoplastic polyneuropathy 12.0
45 aplasia of extensor muscles of fingers, unilateral, with generalized polyneuropathy 12.0
46 charcot-marie-tooth disease, x-linked recessive, 5 11.9
47 polyneuropathy due to drug 11.9
48 axonal polyneuropathy associated with igg/igm/iga monoclonal gammopathy 11.9
49 polyneuropathy associated with igm monoclonal gammapathy with anti-mag 11.9
50 guillain-barre syndrome, familial 11.8

Graphical network of the top 20 diseases related to Polyneuropathy:



Diseases related to Polyneuropathy
Sources

Symptoms & Phenotypes for Polyneuropathy

About this section

UMLS symptoms related to Polyneuropathy:


neuralgia

MGI Mouse Phenotypes related to Polyneuropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.09 ABHD12 AKR1B1 APOA1 ARSA CD40LG CD59
2 cellular MP:0005384 10.03 APOA1 CD40LG CD59 GDAP1 GSN MBP
3 behavior/neurological MP:0005386 10.02 PNPLA6 ABHD12 AKR1B1 ARSA DMXL2 GDAP1
4 nervous system MP:0003631 9.77 MAG MBP MPZ PMP22 PNPLA6 SLC25A19
5 reproductive system MP:0005389 9.23 CD40LG CD59 DMXL2 GSN MBP MPZ
Sources

Drugs & Therapeutics for Polyneuropathy

About this section

Drugs for Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 322)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Imipramine Approved Phase 4 50-49-7 3696
2
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 148553-50-8 5486971
3
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 137-58-6 3676
4
Lenalidomide Approved Phase 4,Phase 2 191732-72-6 216326
5 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
6
Citalopram Approved Phase 4 59729-33-8 2771
7
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
8
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
9
Mexiletine Approved, Investigational Phase 4,Phase 2 31828-71-4 4178
10
Norepinephrine Approved Phase 4,Phase 2 51-41-2 439260
11
Nortriptyline Approved Phase 4 72-69-5 4543
12
Capsaicin Approved Phase 4,Phase 2,Phase 3 404-86-4 1548943
13
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 51-84-3 187
14
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
15
Oxcarbazepine Approved Phase 4 28721-07-5 34312
16
alemtuzumab Approved, Investigational Phase 4,Phase 2 216503-57-0
17
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-30-3 6037
19 Etiracetam Investigational Phase 4,Phase 2 33996-58-6
20 Adrenergic Agents Phase 4,Phase 3,Phase 2
21 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Antidepressive Agents Phase 4,Phase 2
25 Antidepressive Agents, Tricyclic Phase 4
26 calcium channel blockers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Nootropic Agents Phase 4,Phase 2,Phase 3
35 Protective Agents Phase 4,Phase 2,Phase 3,Early Phase 1
36 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
37 Anti-Arrhythmia Agents Phase 4,Phase 2,Not Applicable
38 Diuretics, Potassium Sparing Phase 4,Phase 2,Not Applicable
39 Sodium Channel Blockers Phase 4,Phase 2,Not Applicable
40 Antioxidants Phase 4,Phase 2,Phase 3,Early Phase 1
41 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
42 Thioctic Acid Phase 4,Phase 2,Phase 3
43 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
44 Vitamin B Complex Phase 4,Phase 2,Phase 3
45 Vitamins Phase 4,Phase 2,Phase 3,Phase 1
46 Anesthetics Phase 4,Phase 2,Not Applicable
47 Anesthetics, Local Phase 4,Phase 2,Not Applicable
48 Angiogenesis Inhibitors Phase 4,Phase 2
49 Angiogenesis Modulating Agents Phase 4,Phase 2
50 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 362)
# Name Status NCT ID Phase Drugs
1 Imipramine and Pregabalin Combination in Painful Polyneuropathy Unknown status NCT01047488 Phase 4 Imipramine;Pregabalin;Imipramine, pregabalin;Placebo
2 Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences. Unknown status NCT02033057 Phase 4
3 Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy Unknown status NCT01770964 Phase 4 Pregabalin;placebo
4 Effects of Pregabalin on Mechanical Hyperalgesia Unknown status NCT00310583 Phase 4 Pregabalin
5 Levetiracetam for Painful Polyneuropathy Completed NCT00286260 Phase 4 levetiracetam
6 Escitalopram as a Treatment for Pain in Polyneuropathy Completed NCT00162968 Phase 4 escitalopram
7 Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines Completed NCT01076478 Phase 4 Cilostazol
8 Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations Completed NCT02260388 Phase 4 Nortriptyline;Duloxetine;Pregabalin;Mexiletine
9 A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment Completed NCT01713426 Phase 4 Qutenza;Pregabalin
10 Alpha Lipoic Acid for Treatment of Diabetic Neuropathy Completed NCT02439879 Phase 4 Alpha lipoic acid
11 Botulinum Toxin in Peripheral Neuropathic Pain Completed NCT01251211 Phase 4 botulinum toxin type A
12 Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain Completed NCT01302275 Phase 4 Oxcarbazepine
13 Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy Completed NCT00903851 Phase 4 Lidoderm
14 Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus Completed NCT01408199 Phase 4 Lenalidomide
15 Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder Completed NCT00844194 Phase 4 Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 90 mg QD;Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 120 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 120 mg QD
16 Effect of Pulsing Electrical Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
17 Postoperative Alpha Lipoic Acid in the Carpal Tunnel Syndrome: a Randomized Controlled Trial. Completed NCT01895621 Phase 4
18 IVIg for Demyelination in Diabetes Mellitus Recruiting NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
19 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
20 Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy Terminated NCT00832572 Phase 4 Ranolazine;Placebo
21 Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin Withdrawn NCT01116531 Phase 4 Tramadol;Duloxetine;Pregabalin
22 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
23 Lidocaine and Triamcinolone vs Saline Trigger Point Injection for Treatment of Chronic Abdominal Wall Pain Withdrawn NCT02748395 Phase 4 Triamcinolone;Lidocaine
24 Efficacy and Safety Study of Thioctacid Oral Tablets 600mg to Treat Chinese Diabetic Patients With Distal Symmetric Polyneuropathy Unknown status NCT01224353 Phase 2, Phase 3 lipoic acid
25 Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD) Unknown status NCT01868191 Phase 3 Benfotiamine;Placebo for benfotiamine
26 Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program for Charcot−Marie−Tooth Neuropathy Type 1A (CMT1A) Unknown status NCT01289704 Phase 2, Phase 3
27 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
28 Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM) Completed NCT00483730 Phase 3 Deproteinised hemoderivative of calf blood (Actovegin)
29 RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy Completed NCT00259974 Phase 3 Rituximab
30 Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) Completed NCT00977483 Phase 3 Thioctic Acid;Placebo
31 Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy Completed NCT00927914 Phase 2, Phase 3 Ranirestat;Placebo
32 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
33 Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy Completed NCT01737398 Phase 2, Phase 3 Inotersen;Placebo
34 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
35 The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin Completed NCT01435655 Phase 3 tafamidis
36 An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy Completed NCT00791492 Phase 2, Phase 3 Fx-1006A
37 Neuropathic Pain Management Completed NCT01263132 Phase 3 F0434;Gabapentin
38 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
39 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
40 Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis Completed NCT00409175 Phase 2, Phase 3 Fx-1006A;Placebo
41 Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy Completed NCT00101426 Phase 3 ranirestat, (AS-3201)
42 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
43 Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy Completed NCT00993070 Phase 2, Phase 3 Capsaicin;placebo
44 The Effect of Diflunisal on Familial Amyloidosis Completed NCT00294671 Phase 2, Phase 3 diflunisal
45 Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Completed NCT00328601 Phase 3 Thioctic Acid
46 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
47 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
48 Evaluate The Efficacy and Safety Of Pregabalin In Prevention, Reduction of Oxaliplatin-Induced Painful Neuropathy Completed NCT01450163 Phase 3 Pregabalin, Oxaliplatin;Placebo , Oxaliplatin
49 APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis Completed NCT01960348 Phase 3 patisiran (ALN-TTR02);Sterile Normal Saline (0.9% NaCl)
50 Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy Completed NCT03050827 Phase 3 3% oxybutynin;Placebo

Search NIH Clinical Center for Polyneuropathy

Cochrane evidence based reviews: polyneuropathies

Sources

Genetic Tests for Polyneuropathy

About this section

Genetic tests related to Polyneuropathy:

# Genetic test Affiliating Genes
1 Polyneuropathy 29
Sources

Anatomical Context for Polyneuropathy

About this section

MalaCards organs/tissues related to Polyneuropathy:

41
Liver, Skin, Testes, Spinal Cord, Brain, Heart, Bone
Sources

Publications for Polyneuropathy

About this section

Articles related to Polyneuropathy:

(show top 50) (show all 2283)
# Title Authors Year
1
Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab. ( 29382383 )
2018
2
Lenalidomide-Induced Ischemic Cerebrovascular Disease in Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome. ( 29395638 )
2018
3
Is Regenerative Medicine Ready for Prime Time in Diabetic Polyneuropathy? ( 29383511 )
2018
4
Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study. ( 29869146 )
2018
5
Acute mitochondrial myopathy with respiratory insufficiency and motor axonal polyneuropathy. ( 28969510 )
2018
6
Neurophysiological study of critical illness polyneuropathy and myopathy in mechanically ventilated children; additional aspects in paediatric critical illness comorbidities. ( 29604150 )
2018
7
Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. ( 29343286 )
2018
8
Chronic inflammatory demyelinating polyneuropathy misdiagnosis: A clinical more than electrophysiogical problem? ( 29406592 )
2018
9
IgPro20, the Polyneuropathy and Treatment with Hizentra<sup>Ar</sup> study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG. ( 29764262 )
2018
10
Onset of fulminant type 1 diabetes mellitus under immunotolerance status after long-term therapy for chronic inflammatory demyelinating polyneuropathy. ( 29905029 )
2018
11
Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy. ( 29182448 )
2018
12
Clinical spectrum and quality of life in patients with chronic polyneuropathy: A cross-sectional study. ( 29687564 )
2018
13
Octagam<sup>Ar</sup> for chronic inflammatory demyelinating polyneuropathy: results from three observational studies. ( 29517417 )
2018
14
Nocebo in chronic inflammatory demyelinating polyneuropathy; a systematic review and meta-analysis of placebo-controlled clinical trials. ( 29627036 )
2018
15
Specific symptoms may discriminate between fibromyalgia patients with vs without objective test evidence of small-fiber polyneuropathy. ( 29430562 )
2018
16
A novel paraneoplastic syndrome with acquired lipodystrophy and chronic inflammatory demyelinating polyneuropathy in an adolescent male with craniopharyngioma. ( 29455190 )
2018
17
Vestibular impairment in chronic inflammatory demyelinating polyneuropathy. ( 29260355 )
2018
18
Sensory nerve degeneration in a mouse model mimicking early manifestations of familial amyloid polyneuropathy due to transthyretin Ala97Ser. ( 29423915 )
2018
19
Difference in normal limit values of nerve conduction parameters between Westerner and Japanese people may need to be considered when diagnosing diabetic polyneuropathy using a Point-of-Care Sural Nerve Conduction Device(NC-stat<sup>a98</sup>/DPNCheck<sup>a8c</sup>). ( 29430866 )
2018
20
Sonographic assessment of carpal tunnel syndrome in diabetic patients with and without polyneuropathy. ( 29901629 )
2018
21
A brain-based pain facilitation mechanism contributes to painful diabetic polyneuropathy. ( 29346515 )
2018
22
Heterozygosity for CMT Type 4 Predicts a Severe Vincristine-induced Polyneuropathy Phenotype: A Case Report and Review of Literature. ( 29877907 )
2018
23
Elevated serum levels of endothelin-1 in patients with chronic inflammatory demyelinating polyneuropathy. ( 29137897 )
2018
24
Increased Prevalence of Polyneuropathy inA Parkinson's Disease Patients: AnA Observational Study. ( 29154292 )
2018
25
Standing postural reaction to visual and proprioceptive stimulation in chronic acquired demyelinating polyneuropathy. ( 29313871 )
2018
26
Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. ( 29968199 )
2018
27
CD59 deficiency presenting as polyneuropathy and Moyamoya syndrome with endothelial abnormalities of small brain vessels. ( 29843966 )
2018
28
Laboratory Abnormalities in Polyneuropathy and Electrophysiological Correlations. ( 29433597 )
2018
29
The value of electrochemical skin conductance measurement using SudoscanAr in the assessment of patients with familial amyloid polyneuropathy. ( 29883834 )
2018
30
Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients. ( 29603827 )
2018
31
IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety. ( 29403541 )
2018
32
Assessment of vestibular-evoked myogenic potentials and video head impulse test in type 2 diabetes mellitus patients with or without polyneuropathy. ( 29330601 )
2018
33
Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. ( 29907605 )
2018
34
FIBROMYALGIA AND SMALL FIBER POLYNEUROPATHY: WHAT'S IN A NAME? ( 29938813 )
2018
35
A chemometric approach for characterization of serum transthyretin in familial amyloidotic polyneuropathy type I (FAP-I) by electrospray ionization-ion mobility mass spectrometry. ( 29426546 )
2018
36
Impaired thiol-disulphide homeostasis in patients with axonal polyneuropathy. ( 29359643 )
2018
37
Risk Factors for Incident Diabetic Polyneuropathy in a Cohort With Screen-Detected Type 2 Diabetes Followed for 13 Years: ADDITION-Denmark. ( 29487078 )
2018
38
Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy. ( 29122522 )
2018
39
Neurofascin and Compact Myelin Antigen-Specific T Cell Response Pattern in Chronic Inflammatory Demyelinating Polyneuropathy Subtypes. ( 29615965 )
2018
40
Elevated leukocyte count in cerebrospinal fluid of patients with chronic inflammatory demyelinating polyneuropathy. ( 29341326 )
2018
41
Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: a randomized double-blind placebo-controlled study in Japan. ( 29975462 )
2018
42
Long-Term Spinal Cord Stimulation Alleviates Mechanical Hypersensitivity and Increases Peripheral Cutaneous Blood Perfusion in Experimental Painful Diabetic Polyneuropathy. ( 29522270 )
2018
43
Possible Combined Central and Peripheral Demyelination Presenting as Optic Neuritis, Cervical Myelitis, and Demyelinating Polyneuropathy with Marked Nerve Hypertrophy. ( 29540658 )
2018
44
Bilateral facial nerve palsies secondary to chronic inflammatory demyelinating polyneuropathy following adalimumab treatment. ( 29179036 )
2018
45
Diabetic polyneuropathy, deep white matter lesions, and carotid atherosclerosis: is there any association? ( 29063451 )
2018
46
The ulnar ratio as a sensitive and specific marker of acute inflammatory demyelinating polyneuropathy. ( 29940481 )
2018
47
Drug-induced hypersensitivity syndrome followed by chronic inflammatory demyelinating polyneuropathy. ( 29671897 )
2018
48
Characterization of the Nile Grass Rat as a Unique Model for Type 2 Diabetic Polyneuropathy. ( 29718319 )
2018
49
Polyneuropathy and myopathy in beta-thalassemia major patients. ( 29427184 )
2018
50
Physical interventions for patients suffering from chemotherapy-induced polyneuropathy. ( 29374785 )
2018
Sources

Variations for Polyneuropathy

About this section

ClinVar genetic disease variations for Polyneuropathy:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 GDAP1 NM_018972.2(GDAP1): c.715C> T (p.Leu239Phe) single nucleotide variant Pathogenic rs104894080 GRCh37 Chromosome 8, 75276240: 75276240
2 GDAP1 NM_018972.2(GDAP1): c.715C> T (p.Leu239Phe) single nucleotide variant Pathogenic rs104894080 GRCh38 Chromosome 8, 74364005: 74364005
3 ERCC5 NM_000123.3(ERCC5): c.2929_2930delCT (p.Leu977Valfs) deletion Likely pathogenic rs1057518813 GRCh37 Chromosome 13, 103525658: 103525659
4 ERCC5 NM_000123.3(ERCC5): c.2929_2930delCT (p.Leu977Valfs) deletion Likely pathogenic rs1057518813 GRCh38 Chromosome 13, 102873308: 102873309
5 SMC1A NM_006306.3(SMC1A): c.2981A> G (p.Gln994Arg) single nucleotide variant Uncertain significance rs781817923 GRCh37 Chromosome X, 53410167: 53410167
6 SMC1A NM_006306.3(SMC1A): c.2981A> G (p.Gln994Arg) single nucleotide variant Uncertain significance rs781817923 GRCh38 Chromosome X, 53383246: 53383246
Sources

Expression for Polyneuropathy

About this section
Search GEO for disease gene expression data for Polyneuropathy.
Sources

Pathways for Polyneuropathy

About this section

Pathways related to Polyneuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Guidance Cues and Growth Cone Motility 64
11.5 GDAP1 GSN MAG
2
Neural Crest Differentiation 1
11.14 MBP MPZ PMP22
3
Diseases associated with visual transduction 66
Show member pathways
 10.43 RBP4 TTR
4
Glial Cell Differentiation 1
9.53 MAG MBP
Sources

GO Terms for Polyneuropathy

About this section

Cellular components related to Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.97 AKR1B1 APOA1 ARSA CD59 GSN MT-ATP6
2 extracellular space GO:0005615 9.65 AKR1B1 APOA1 ARSA CD40LG CD59 DMXL2
3 myelin sheath GO:0043209 9.46 GSN MAG MBP MPZ
4 Schmidt-Lanterman incisure GO:0043220 9.26 AKR1B1 MAG
5 compact myelin GO:0043218 8.8 MAG MBP PMP22

Biological processes related to Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.58 ARSA GSN RBP4
2 negative regulation of viral entry into host cell GO:0046597 9.43 GSN IFNA2
3 phosphatidylcholine metabolic process GO:0046470 9.37 APOA1 PNPLA6
4 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.32 MAG MPZ
5 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.26 APOA1 MBP
6 glycerophospholipid catabolic process GO:0046475 9.16 ABHD12 PNPLA6
7 retinoid metabolic process GO:0001523 9.13 APOA1 RBP4 TTR
8 myelination GO:0042552 8.8 MBP MPZ PMP22

Molecular functions related to Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lysophospholipase activity GO:0004622 8.62 ABHD12 PNPLA6
Sources

Sources for Polyneuropathy

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....